Researcher receives $7,637 funding for thrombus proteomic analysis

Virginia Espina, Research Associate Professor, Applied Proteomics and Molecular Medicine, received $7,637 from Mayo Clinic for: "Thrombus proteomic analysis."

This collaboration between Mason and Mayo Clinic is a pilot study to demonstrate utility of RPPA technology in ischemic stroke specimens. Fifty (50) thrombus specimens will be provided by Mayo Clinic to Mason. The specimens may be frozen, formalin fixed or ethanol fixed.

Espina will lyse the thrombus specimens, determine the total protein content, and print the specimens, in triplicate, on 25-30 RPPA slides. Each array will be probed with a single primary antibody to the protein of interest. The proteins of interest will be determined jointly based on research hypotheses and availability of validated antibodies.

Arrays will be quantified with spot analysis software, data will be normalized across specimens, and statistical/bioinformatic analyses will be performed. RPPA data (raw and normalized) will be provided to Mayo Clinic researchers in an Excel spreadsheet.

Funding for this project began in September 20, 2019 and will conclude in late August 2020.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development